Research Article

Frequencies of CYP2B6*4, *5, and *6 Alleles within an Iranian Population (Mazandaran)

Mohammad Bagher Hashemi-Soteh, Elahe Hosseini, Shokoufeh Fazelnia, Faramarz Ghasemian-Sorbeni, Sara Madahian, and Mohammad Reza Shiran

*Immunogenetic Research Center, Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
1Novin Genetic Diagnostic Laboratory, FarahAbad Boulevard, Sari, Mazandaran, Iran
2The Health of Plant and Livestock Products Research Center, Mazandaran University of Medical Sciences, Sari, Iran

Correspondence should be addressed to Mohammad Bagher Hashemi-Soteh; hashemisoteh@mazums.ac.ir

Received 24 September 2021; Revised 15 November 2021; Accepted 22 November 2021; Published 2 December 2021

Academic Editor: Hafiz Ishfaq Ahmad

Copyright © 2021 Mohammad Bagher Hashemi-Soteh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The human CYP2B subfamily consists of one functional gene (CYP2B6) and one pseudogene (CYP2B7P). Cytochrome P450 2B6 (CYP2B6) is a highly polymorphic enzyme that shows marked interindividual and interethnic variations. Currently, 38 alleles have been described, and some of the allelic variants have been associated with low enzyme activity. The aim of this study was to investigate the frequencies of CYP2B6*4, CYP2B6*5, and CYP2B6*6 alleles in the Mazani ethnic group among Iranian Population. Methods. The study was conducted in 289 unrelated healthy volunteers. DNA was extracted from peripheral blood and analyzed by the PCR-RFLP protocol. The PCR product was digested with restriction enzymes and then separated using agarose gel electrophoresis. Results. The frequency of CYP2B6*4, CYP2B6*5, and CYP2B6*6 in this study was 34.60%, 7.26%, and 34.54%, respectively. Conclusion. The frequency of the CYP2B6*4 allele in the Mazani ethnic group was much higher (34.60%) than other population. The frequency of CYP2B6*6 (34.54%) also was higher than its frequency in other previously reported population. But the frequency of CYP2B6*5 in this study was lower than expected. These results will be useful in understanding the ethnic diversity in Iranian population and offer a preliminary basis for more rational use of drugs that are substrates for CYP2B6 in this population.

1. Introduction

Polymorphisms are the cause of 15–30% of individual difference in the drug metabolism [1, 2]. The human CYP is a superfamilly which is expressed in the liver. 57 polymorphic genes containing a large number of SNVs and CNVs belong to this superfamilly [3]. One of the most polymorphic gene in this familly is CYP2B6, which is located on 19q13.2 within CYP2 gene cluster [4, 5].

Cytochrome p402B6 (CYP2B6) is known as one of the important subclasses for drug metabolizing enzyme in the liver and other organs. Polymorphisms of this gene cause differences in transcriptional regulation, splicing, and expression of mRNA and protein [5].

CYP2B6 is involved in the metabolism and metabolic activation of many clinically important drugs such as antiretrovirals, efavirenz, and nevirapine; the antidepressants bupropion, sertraline; the antiestrogen tamoxifen; the synthetic opioid methadone; the anti-Parkinsonian selegiline; the antimalarial artemisinin, ketamine, and propofol; and cytotoxic prodrugs cyclophosphamide, ifosfamide, thiotepa, and procarbazine [6–9].

The CYP2B6 gene is mainly expressed in the liver cells, where it makes about 3–5% of the total microsomal P450 pool [10–12]. It is also active at lower levels in extrahepatic tissues, including the intestine, kidney, lung, skin, and brain [13, 14]. CYP2B6 expression levels in human livers vary from 20 to 250 folds between different individuals, while CYP2B6
activity in liver microsomes varies more than 100 folds [15–17]. Transcriptional regulation is considered to be one of the major contributors to this variability. CYP2B6 is highly inducible by phenobarbital-type compounds as well as many other typical inducers of CYP3A4 in a dose-dependent manner [18–20]. Furthermore, the differences in gene regulation and genetic polymorphisms largely contribute to interindividual variability in CYP2B6 activity. Currently, 38 alleles have been described for CYP2B6 [21]. Low enzyme activity is the result of some allelic variants. These variants include single nucleotide polymorphisms (SNPs) located in the coding region, such as CYP2B6*4A (c.785 A > G), CYP2B6*5A (c.1459 C > T), and CYP2B6*6A (c.516 G > T). Among these alleles, CYP2B6*6 as an allele with high frequency in different ethnic and population (15–60%) is noticeable [5]. In the present study, we examined the frequencies of CYP2B6*4 (rs2279343), CYP2B6*5 (rs3211371), and *6 (rs3745274) mutant alleles in the Mazani ethnic group among Iranian population.

2. Materials and Methods

2.1. Subjects. 289 unrelated healthy volunteers of Mazani origin, residing in Mazandaran, a northern province in Iran, were enrolled in the study. The investigation workflow was approved by the Research Ethics Committee of Mazandaran University of Medical Sciences. All subjects were included in the study after signing the consent form.

2.2. Genomic DNA Extraction. 5–10 ml venous blood was obtained from each subject and stored in an Na-EDTA tube at −25°C until processing. Lymphocytic genomic DNA was extracted by the Nucleon BACCII method [22], followed by DNA concentrations measurement using the NanoDrop instrument (Biowave, UK).

2.3. PCR Amplification of the CYP2B6 Alleles. Allele-specific PCR was carried out to detect CYP2B6*4, CYP2B6*5, and CYP2B6*6 alleles and their genotype frequency, respectively. The specific primers were used to amplify each CYP2B6 allele separately (Table 1). The total volume of each PCR reaction was 25 μl containing 0.6 μl forward primers and 0.6 μl reverse primers, 2 μl DNA template, and 11 μl EmeraldAmp PCR master mix (Takara Bio Inc., Japan), up to 25 μl dH2O. The PCR reactions were carried out with the following conditions: 93°C, 40 s; annealing temperature for 40 s; 72°C, 40 s; for 35 cycles. PCR products were visualized on 1% agarose gel.

2.4. Genotyping of the CYP2B6*4 Allele. PCR products of CYP2B6*4 revealed a 640 bp band and were digested using StyI restriction enzyme as previously reported [23, 24]. 0.3 μl of StyI enzyme and 1 μl enzyme buffer were added to 6 μl of CYP2B6*4 PCR product and 3 μl distilled water. The reaction tubes were incubated overnight at 37°C prior to analysis on 3% agarose gel. Mutant allele created three different bands (56, 116, and 468 bp), while the normal case showed four separate bands, containing 56, 116, 171, and 297 bp. The size of the DNA fragments was determined by comparing with a standard size marker DNA ladder (Figure 1).

2.5. Genotyping of the CYP2B6*5 Allele. The PCR product for CYP2B6*5 revealed a 600 bp band. After digestion using the BglII restriction enzyme, mutant allele showed two bands, 504 bp and 96 bp, but the enzyme did not cut the wild type 600 bp original band, genotype *1/*1. The reaction tubes were incubated overnight at 37°C prior to analysis on a 3% agarose gel (Figure 1).

2.6. Genotyping of the CYP2B6*6 Allele. The PCR product for CYP2B6*6 was a 401 bp fragment. After digestion using the BsrI restriction enzyme, three bands were created in the gel including 28, 105, and 268 bp for the wild type. Also, the enzyme on the mutant allele produced two distinct bands including 28 bp and 373 bp (Figure 1).

2.7. DNA Sequencing. In order to confirm the RFLP results, some samples were subjected to DNA sequencing using specific primers (Table 2). A DNA sequence analysis software, GeneRunner (https://www.generunner.com), was applied along with using reference sequences from GenBank database. Finch TV, a DNA sequence chromatogram viewer software (Geospiza, Inc., USA), also was applied (Figure 2) to view nucleotide changes. Figure 2 shows two nucleotide change, CYP2B6*5 (rs3211371) and CYP2B6*6 (rs3745374), in CYP2B6 gene [25, 26].

3. Results

In total, 289 individuals from Mazandaran province (Mazani ethnics) were tested for 3 different polymorphisms in CYP2B6 gene. Frequencies of the three polymorphisms including CYP2B6*4, CYP2B6*5, and CYP2B6*6 in 289 individuals are provided in Table 3. The frequency of polymorphic CYP2B6 alleles responsible for impaired drug metabolisms CYP2B6*4, *5, and *6 was 34.60%, 7.26%, and 34.54%, respectively (Table 3).

4. Discussion

Different ethnic groups live in various parts of Iran. These ethnic groups include Persian, Azari, Turkmen, Kurd, Arab, Lor, Balouch, Gilaki, and Mazani [27]. Whereas CYP2B6 genetic polymorphisms have previously been assessed in other population and southern Iranians [21], there is a lack of data in the Mazani ethnic group.

The CYP2B6 polymorphism is characterized by numerous variants in both coding and noncoding regions of the gene. The website of CYP alleles (https://www.pharmvar.org) lists 38 distinct alleles for CYP2B6 gene (accessed April 2021). In human livers, CYP2B6*6 has been associated with lower protein expression and lower hydroxylation activity towards efavirenz and bupropion [28]. CYP2B6*6 variant S16G>T (Q172H) is involved in the posttranscriptional
mechanism and causes an aberrant splicing which results in missing of exons 4–6 in mRNA transcripts and causes lower expression of CYP2B6 protein [29]. In vivo, CYP2B6∗6 has been consistently associated with higher plasma levels of efavirenz during treatment [30]. At least half of the patients who receive efavirenz faced with central nervous system (CNS) side effects are thought to be a reflect of higher efavirenz plasma concentrations [31, 32]. Interestingly, Gatanaga et al. were able to successfully employ CYP2B6∗6 genotyping to reduce the therapeutic dose of efavirenz and improve the CNS-related side effects [33]. The CYP2B6∗6 variant allele has a frequency between 15% and over 50% across different populations, which has the highest frequencies in African and the lowest in Asians populations, respectively (Table 4). Ethnicity is an important variable contributing to interindividual variability in the drug metabolism, response, and toxicity [34].

![Figure 1: The restriction analysis result for CYP2B6∗4, ∗5, and ∗6 variants in Mazani ethnic group people. StyI enzyme cuts the normal variant to 56, 116, 171, and 297bp and mutated allele of ∗4 to 56, 116, and 468bp. BglII does not cut the normal variant (600bp) and just make the mutant ∗5 allele to 96 and 504bp. Finally, BsrI digest the normal variant to 28, 105, 268bp and ∗6 allele to 28 and 373bp.]

![Table 1: Specific primers for amplification and evaluation of each CYP2B6 defective allele.](https://example.com/table1)

| CYP2B6 allele | Specific primer pairs | Annealing Tm | PCR product sizes |
|--------------|-----------------------|--------------|------------------|
| ∗4           | F: 5′GACAGAAGGTGAGGGAGGAAG 3′  
R: 5′CTCCTCTGTGCTTTTCAATTGCTG3′        | 59°C          | 640 bp          |
| ∗5           | F: 5′ACAAGATCTTTGGAACCGACCTG3′  
R: 5′ATCAGATGCACTTGTCTACAG3′        | 59°C          | 600 bp          |
| ∗6           | F: 5′TCTCCTCTGCCCATTATATAC3′  
R: 5′CCTGACCTGGAATACA3′        | 59°C          | 401 bp          |

![Figure 2: DNA sequence chromatogram showing nucleotide change position. (a) A missense nucleotide transition C>T in c.1483 of CYP2B6 gene, a heterozygous sample for CYP2B6∗5 (rs3211371) polymorphism. (b) A normal sample with major allele G in c.540 G>T of CYP2B6 gene for CYP2B6∗6 (rs3745374) polymorphism.](https://example.com/table2)

![Table 2: Specific primers for PCR sequencing.](https://example.com/table2)

| CYP2B6 allele | Specific primer pairs | Annealing Tm | PCR product sizes |
|--------------|-----------------------|--------------|------------------|
| ∗5           | F: 5′AGCCGATTTTCTCTGTTGAA 3′  
R: 5′ACCTGAATGACCCCTGGAAATCC3′        | 59°C          | 225 bp          |
| ∗6           | F: 5′AGCCTCTCGGTCTGCCCATCTATA3′  
R: 5′CCTGTCCCTCTCCGTCTCCCTGA3′        | 64°C          | 423 bp          |
Also, in human livers, CYP2B6*5 is associated with lower protein expression, bupropion hydroxylation, and S-mephenytoin N-demethylation [12]. The alleles show the highest (12.8%) and the lowest (0.1%) frequency in Europe and East Asia, respectively [35]. Despite lack of CYP2B6*5 alleles in Korean or Chinese populations, its frequency in different European countries is considerable and around 10–15% (Table 4). The 7.26% frequency of CYP2B6*5 found in the Mazani ethnic group in this study is comparable to those found in African and Japanese. By contrast, it occurs at a relatively lower frequency in Caucasian and African-American (Table 4). Notably, no clear effect on CYP2B6 functionality has been revealed for CYP2B6*5 [35]. Although in vitro studies have clearly represented an association between CYP2B6*5 variant and decreased activity and protein expression [36], but in vivo studies have not shown any effect of CYP2B6*5 on efavirenz pharmacokinetics and reported lack of a significant phenotype-genotype association [37, 38]. This difference in results can be explained by an increased specific activity of the gene product towards efavirenz, which may compensate an inherent low expression [39, 40]. Thus, it is important for future studies to investigate under which conditions a lower frequency of CYP2B6*5 could be clinically important.

Interestingly, CYP2B6*4, emerged by a gain of function mutation, is relevant to high level of gene expression and may lead to a moderate substrate-dependent effects. As a result, a disruption occurs in the hydroxylation process in the metabolism of some relevant drugs such as bupropion, efavirenz, propofol, and clotiazepam [5]. A relatively low prevalence for *4 allele in different populations was demonstrated by previous investigations. This allele frequency was reported 5% in Germany [41], 2.2% in Caucasian in New Zealand, 3.3% in Chinese, and 6% in United States, respectively [42–45]. The results of current research showed a frequency of 34.60% for the CYP2B6*4 minor allele (G) (Table 3), which is significantly higher than its frequency in other parts of the world. Table 4 provides the frequency of some other relevant studies from different countries.

The global distribution for CYP2B6*6 is reported 73% and 26% for the G and T alleles, respectively [51]. The frequency of CYP2B6 minor allele (T) is estimated about 21.5% in East Asian and 38.1% in South Asian [52] (Table 4). In Pakistan population, eastern neighbor of Iran, the frequency of CYP2B6*6 minor allele (T) is reported about 33.8% [51]. Frequency of CYP2B6*6 achieved in the current study is 34.54% (Table 3), slightly more than East Asia and Pakistan. According to the 1000 Genome project, the lowest frequency of CYP2B6*4 minor allele (G) is reported from European with 8.8% and in South Asian with highest frequency of 25.2%, respectively (Table 5) [52]. Frequency of CYP2B6*4 achieved in the current study is 34.60% (Table 3).

5. Conclusion

The result of this study will aid in understanding the ethnic diversity of the Iranian population and offer a preliminary basis for more rational use of drugs that are substrates for CYP2B6 in this population.
Data Availability
The data used to support the findings of this study are included within the article and are made available from the corresponding author upon request.

Conflicts of Interest
The authors declare that there are no conflicts of interest.

Authors’ Contributions
MB Hashemi-soteh and MR Shiran conceptualized and designed the study. E. Hosseini, Sh. Fazelnia, and S. Maddahian performed lab work. Sh. Fazelnia and F. Ghasemian-Sorbeni analyzed and interpreted data. MB Hashemi-soteh and E. Hosseini drafted the manuscript. MB Hashemi-soteh and E. Hosseini critically revised the study. E. Hosseini performed statistical analysis.

Acknowledgments
This study was funded by Mazandaran University of Medical Sciences (1968).

References
[1] M. Eichelbaum, M. Ingelman-Sundberg, and W. E. Evans, "Pharmacogenomics and individualized drug therapy," Annual Review of Medicine, vol. 57, no. 1, pp. 119–137, 2006.
[2] V. Lauschke and M. Ingelman-Sundberg, "The importance of patient-specific factors for hepatic drug response and toxicity," International Journal of Molecular Sciences, vol. 17, no. 10, Article ID 1714, 2016.
[3] S. M. Peko, F. Ntoumi, C. Vouvoungui et al., "Distribution of the cytochrome P450 CYP2C8*2 allele in brazzaville, republic of Congo," International Journal of Infectious Diseases, vol. 85, pp. 49–53, 2019.
[4] M. H. Hofmann, J. K. Blievernicht, K. Klein et al., "Aberrant splicing caused by single nucleotide polymorphism c.516G>T (Q172H), a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver," Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 1, pp. 284–292, 2008.
[5] U. M. Zanger and K. Klein, "Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance," Frontiers in Genetics, vol. 4, p. 24, 2013.
[6] J. K. Coller, N. Krebs-Zaenger, K. Klein et al., "The influence of CYP2C9 and CYP2D6genotypes on the formation of the potent antiestrogen Z-4-hydroxy-tamoxifen in human liver," British Journal of Clinical Pharmacology, vol. 54, no. 2, pp. 157–167, 2002.
[7] P. Roy, L. J. Yu, C. L. Crespi, and D. J. Waxman, "Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles," Drug Metabolism and Disposition: The Biological Fate of Chemicals, vol. 27, no. 6, pp. 655–666, 1999.
[8] H. Wang and L. Tompkins, "CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme," Current Drug Metabolism, vol. 9, no. 7, pp. 598–610, 2008.
[9] B. A. Ward, J. C. Gorski, D. R. Jones, S. D. Hall, D. A. Flockhart, and Z. Desta, "The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity," Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 1, pp. 287–300, 2003.
[10] E. L. Code, C. L. Crespi, B. W. Pennman, F. J. Gonzalez, T. K. Chang, and D. J. Waxman, "Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation," Drug Metabolism and Disposition, vol. 25, no. 8, pp. 985–993, 1997.
[11] I. H. Hanna, J. R. Reed, F. P. Guengerich, and P. F. Hollenberg, "Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver," Archives of Biochemistry and Biophysics, vol. 376, no. 1, pp. 206–216, 2000.
[12] T. Lang, K. Klein, J. Fischer et al., "Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver," Pharmacogenetics, vol. 11, no. 5, pp. 399–415, 2001.
[13] L. Gervot, B. Rochat, J. C. Gautier et al., "Human CYP2B6," Pharmacogenetics, vol. 9, no. 3, pp. 295–306, 1999.
[14] S. Miksys, C. Lerman, P. G. Shields, D. C. Mash, and R. F. Tyndale, "Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain," Neuropharmacology, vol. 45, no. 1, pp. 122–132, 2003.
[15] S. Ekins, M. Vandenbranden, B. J. Ring et al., "Further characterization of the expression in liver and catalytic activity of CYP2B6," Journal of Pharmacology and Experimental Therapeutics, vol. 286, no. 3, pp. 1253–1259, 1998.
[16] B. Goodwin, L. B. Moore, C. M. Stoltz, D. D. McKee, and S. A Kliewer, "Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor," Molecular Pharmacology, vol. 60, no. 3, pp. 427–431, 2001.
[17] H. Wang, S. Faucette, T. Sueyoshi et al., "A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression," Journal of Biological Chemistry, vol. 278, no. 16, pp. 14146–14152, 2003.
[18] S. R. Faucette, T. Sueyoshi, C. M. Smith, M. Negishi, E. L. LeCluyse, and H. Wang, "Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor," Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 3, pp. 1200–1209, 2006.
[19] S. R. Faucette, H. Wang, G. A. Hamilton et al., "Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers," Drug Metabolism and Disposition, vol. 32, no. 3, pp. 348–358, 2004.
[20] H. Wang, S. Faucette, R. Moore, T. Sueyoshi, M. Negishi, and E. LeCluyse, "Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin," Journal of Biological Chemistry, vol. 279, no. 28, pp. 29295–29301, 2004.
[21] S. Zakeri, N. Amiri, S. Pirahmadi, and N Dinparast Djadid, "Genetic variability of CYP2B6 polymorphisms in southeast Iranian population: implications for malaria and HIV/AIDS treatment," Archives of Iranian Medicine, vol. 17, no. 10, pp. 685–91, 2014.
[22] S. M. B. Hashemi-Soteh, F. Sarzare, F. Merat, E. Salehifar, and M.-R. Shiran, "Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3, *4, and *6) within an Iranian population.
Genetic Testing and Molecular Biomarkers, vol. 15, no. 11, pp. 821–825, 2011.

P. Arnaldo, R. E. Thompson, M. Q. Lopes, P. N Suffys, and A. R. Santos, “Frequencies of cytochrome P450 2B6 and 2C8 allelic variants in the Mozambican population,” *Malaysian Journal of Medical Sciences: MJMS*, vol. 20, no. 4, pp. 13–23, 2013.

L. Hananta, I. Astuti, A. H. Sadewa, J. Alice, and J. Hutagalung, “The prevalence of CYP2B6 gene polymorphisms in malaria-endemic population of timor in East nusa tenggara Indonesia,” *Osong Public Health and Research Perspectives*, vol. 9, no. 4, pp. 192–196, 2018.

S. M. B. Hashemi-Soteh, N. Shahabi-Majd, A.-R. Gholizadeh, E. Hosseini, S. S. Mousavi, A. Khoshaein, F. Daneshpour, L. Hananta, I. Astuti, A. H. Sadewa, J. Alice, and P. Arnaldo, R. E. ,X_hompson, M. Q. Lopes, P. N Suffys, and L. M. Hesse, P. He, S. Krishnaswamy et al., “Pharmacogenetic M. Majbouri and S. Fesharaki, “Iran’s multi-ethnic mosaic: a north of Iran,” *Open Journal of Genetics*, vol. 10, no. 3, pp. 51–63, 2020.

M. Majbouri and S. Fesharaki, “Iran’s multi-ethnic mosaic: a 23-year perspective,” *Social Indicators Research*, vol. 145, no. 3, pp. 831–859, 2019.

L. M. Hesse, P. He, S. Krishnaswamy et al., “Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes,” *Pharmacogenetics*, vol. 14, no. 4, pp. 225–238, 2004.

J. G. Restrepo, C. Martinez, A. Garcia-Agündez et al., “Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population,” *Pharmacogenetics and Genomics*, vol. 21, no. 12, pp. 773–778, 2011.

M. Rotger, H. Tegude, S. Colombo et al., “Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals,” *Clinical Pharmacology & Therapeutics*, vol. 81, no. 4, pp. 557–566, 2007.

C. Csajka, C. Marzolini, K. Fattinger et al., “Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection,” *Clinical Pharmacology & Therapeutics*, vol. 73, no. 1, pp. 20–30, 2003.

C. Marzolini, A. Telenti, L. A. Decosterd, G. Greub, J. Biollaz, and T. Buclin, “Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients,” *AIDS*, vol. 15, no. 1, pp. 71–75, 2001.

H. Gatanaga, T. Hayashida, K. Tsuchiya et al., “Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6* and *26*,” *Clinical Infectious Diseases*, vol. 45, no. 9, pp. 1230–1237, 2007.

J. Li, V. Menard, R. L. Benish et al., “Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment,” *Pharmacogenomics*, vol. 13, no. 5, pp. 555–570, 2012.

Y. Zhou, M. Ingelman-Sundberg, and V. Lauschke, “Worldwide distribution of cytochrome P450 allelic: a meta-analysis of population-scale sequencing projects,” *Clinical Pharmacology & Therapeutics*, vol. 102, no. 4, pp. 688–700, 2017.

V. Lamba, J. Lamba, K. Yasuda et al., “Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 Genotype and CAR (constitutive androstanone receptor) expression,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 307, no. 3, pp. 906–922, 2003.

D. Burger, I. Van Der Heiden, C. La Porte et al., “Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism,” *British Journal of Clinical Pharmacology*, vol. 61, no. 2, pp. 148–154, 2006.

A. Saitoh, K. K. Singh, C. A. Powell et al., “An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children,” *AIDS*, vol. 19, no. 4, pp. 371–380, 2005.

Z. Desta, T. Saussele, B. Ward et al., “Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro,” *Pharmacogenomics*, vol. 8, no. 6, pp. 547–558, 2007.

U. M. Zanger, K. Klein, T. Saussele, J. Blevinricht, M. H. Hofmann, and M. Schwab, “Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance,” *Pharmacogenomics*, vol. 8, no. 7, pp. 743–759, 2007.

J. Kirchheiner, C. Klein, I. Meineke et al., “Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6,” *Pharmacogenetics*, vol. 13, no. 10, pp. 619–626, 2003.

S. Guan, M. Huang, E. Chan, X. Chen, W. Duan, and S.-F. Zhou, “Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese,” *European Journal of Pharmaceutical Sciences*, vol. 29, no. 1, pp. 14–21, 2006.

N. A. Helsby, C.-Y. Hui, M. A. Goldthorpe et al., “The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation,” *British Journal of Clinical Pharmacology*, vol. 70, no. 6, pp. 844–853, 2010.

R. M. Jacob, E. C. Johnstone, M. J. Neville, and R. T. Walton, “Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping,” *Clinical Chemistry*, vol. 50, no. 8, pp. 1372–1377, 2004.

H. A. Karunajeewa, K. F. Ilett, K. Dufall et al., “Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria,” *Antimicrobial Agents and Chemistry*, vol. 48, no. 8, pp. 2966–2972, 2004.

R. Koopmans, C. J. van Boxtel, P. A. Kager et al., “The pharmacokinetics of artesunate in after administration of two different suppositories to healthy Vietnamese subjects,” *The American Journal of Tropical Medicine and Hygiene*, vol. 60, no. 2, pp. 244–247, 1999.

Z. Tomas, A. Kuhaneck, T. Škaric-Juric et al., “Distinctiveness of the Roma population within CYP2B6 worldwide variation,” *Pharmacogenomics*, vol. 18, no. 17, pp. 1575–1587, 2017.

J.-Y. Cho, H.-S. Lim, J.-Y. Chung et al., “Haplotype structure and allele frequencies of CYP2B6 in a Korean population,” *Drug Metabolism and Disposition*, vol. 32, no. 12, pp. 1341–1344, 2004.

S. Krishna, T. Planche, T. Agbenyega et al., “Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria,” *Antimicrobial Agents and Chemotherapy*, vol. 45, no. 2, pp. 509–516, 2001.

F. Carano, S. Sarno, S. De Fanti et al., “Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula,” *Annals of Human Biology*, vol. 45, no. 1, pp. 66–71, 2018.

S. Ahmed, S. Khan, K. Janjua, I. Imran, and A. Ullah Khan, “Allelic and genotype frequencies of major CYP2B6 polymorphisms in the Pakistani population,” *Molecular Genetics & Genomic Medicine*, vol. 9, no. 3, Article ID e1527, 2021.

G. P. Consortium, “A global reference for human genetic variation,” *Nature*, vol. 526, no. 7571, p. 68, 2015.